The Experts below are selected from a list of 159 Experts worldwide ranked by ideXlab platform

David J Langer - One of the best experts on this subject based on the ideXlab platform.

  • forearm cephalic Vein graft for short middle flow internal maxillary artery to middle cerebral artery bypass
    Neurosurgery, 2015
    Co-Authors: Erez Nossek, Peter Costantino, David J Chalif, Rafael Ortiz, Amir R Dehdashti, David J Langer
    Abstract:

    BACKGROUND: The cervical carotid system has been used as a source of donor vessels for radial artery or saphenous Vein grafts in cerebral bypass. Recently, internal maxillary artery to middle cerebral artery bypass has been described as an alternative, with reduction of graft length potentially correlating with improved patency. OBJECTIVE: To describe our experience using the forearm cephalic Vein grafts for short segment internal maxillary artery to middle cerebral artery bypasses. METHODS: All Vein grafts were harvested from the volar forearm between the proximal Cubital fossa where the Median Cubital Vein is confluent with the cephalic Vein and the distal wrist. RESULTS: Six patients were treated with internal maxillary artery to middle cerebral artery bypass. In 4, the cephalic Vein was used. Postoperative angiography demonstrated good filling of the grafts with robust distal flow. There were no upper extremity vascular complications. All but 1 patient (mortality) tolerated the procedure well. The other 3 patients returned to their neurological baseline with no new neurological deficit during follow-up. CONCLUSION: The internal maxillary artery to middle cerebral artery "middle" flow bypass allows for shorter graft length with both the proximal and distal anastomoses within the same microsurgical field. These unique variable flow grafts represent an ideal opportunity for use of the cephalic Vein of the forearm, which is more easily harvested than the wider saphenous Vein graft and which has good match size to the M1/M2 segments of the middle cerebral artery. The vessel wall is supple, which facilitates handling during anastomosis. There is lower morbidity potential than utilization of the radial artery. Going forward, the cephalic Vein will be our preferred choice for external carotid-internal carotid transplanted conduit bypass.

Yoichiro Yoshida - One of the best experts on this subject based on the ideXlab platform.

  • administration of chemotherapy via the Median Cubital Vein without implantable central venous access ports port free chemotherapy for metastatic colorectal cancer patients
    International Journal of Clinical Oncology, 2015
    Co-Authors: Yoichiro Yoshida, Seiichiro Hoshino, Naoya Aisu, Masayasu Naito, Syu Tanimura, Ai Mogi, Toshihiro Tanaka, Keiji Hirata, Kazuo Tamura, Yuichi Yamashita
    Abstract:

    Background Repeated venous punctures are usually required during chemotherapy administration for cancer patients. Central venous catheters and implantable port systems have substantially facilitated vascular access, and safe, easy-to-handle port systems have become an integral part of daily clinical routines in oncology. However, several serious complications are associated with central venous ports (CV-ports), and recent developments of combined oral capecitabine and oxaliplatin (XELOX) therapies allow CV-port-free administration. In this study, the safety and efficacy of CV-port-free chemotherapy administration via the Median Cubital Vein was assessed in metastatic colorectal cancer patients.

  • p2 7 6administration of chemotherapy via Median Cubital Vein without central venous access port for colorectal cancer
    Annals of Oncology, 2014
    Co-Authors: Yoichiro Yoshida, Seiichiro Hoshino, Naoya Aisu, Masayasu Naito, Syu Tanimura, Yuichi Yamashita
    Abstract:

    Abstract Background: Repeated venous punctures are usually required in cancer patients for application of chemotherapy. Central venous catheters and implantable port systems have substantially facilitated the problem of vascular access. Safe and easy-to-handle port systems have become an integral part of daily clinical routine in oncology. However, there are several serious complications associated with central venous ports (CV-ports). With the recent development of capecitabine plus oxaliplatin (XELOX) therapy involving oral administration of drug preparations, etc., implantation of a CV-port can be avoided. The present study was undertaken to evaluate the safety of administration of chemotherapy via Median Cubital Vein without CV port for metastatic colorectal cancer. Methods: The study included 144 patients who received XELOX + bevacizumab (BV) therapy and XELOX therapy for metastatic colorectal cancer without implantation of a CV-port. Results: Eighty-five patients experienced vascular pain, but it was transient. The drip infusion route had to be switched to the opposite side because of vascular pain in only 1 of the 144 patients. No patients required CV-port implantation or postponement of treatment due to adverse events caused by administration of the drug via the peripheral Vein. Grade 3 or higher hemotoxicity was noted in 12.5%, and grade 3 or higher nonhematological toxicity was noted in 17.4%. Conclusions: We may be able to perform port-free-chemotherapy via Median Cubital Vein for patients with colorectal cancer. We can avoid the serious complications associated with CV-port.

  • administration of chemotherapy via Median Cubital Vein without implantable central venous access port for metastatic colorectal cancer port free chemotherapy
    Journal of Clinical Oncology, 2014
    Co-Authors: Yoichiro Yoshida, Seiichiro Hoshino, Naoya Aisu, Masayasu Naito, Syu Tanimura, Ai Mogi, Toshihiro Tanaka, Takamitsu Sasaki, Shinsuke Takeno, Kazuo Tamura
    Abstract:

    651 Background: Repeated venous punctures are usually required in cancer patients for application of chemotherapy. Central venous catheters and implantable port systems have substantially facilitated the problem of vascular access. Safe and easy-to-handle port systems have become an integral part of daily clinical routine in oncology. However, there are several serious complications associated with central venous ports (CV-ports). With the recent development of capecitabine plus oxaliplatin (XELOX) therapy involving oral administration of drug preparations, etc., implantation of a CV-port can be avoided. The present study was undertaken to evaluate the safety of administration of chemotherapy via Median Cubital Vein without CV port for metastatic colorectal cancer. Methods: The study included 144 patients who received XELOX + bevacizumab (BV) therapy and XELOX therapy for metastatic colorectal cancer without implantation of a CV-port. Results: Eighty-five patients experienced vascular pain, but it was tra...

Yuichi Yamashita - One of the best experts on this subject based on the ideXlab platform.

  • administration of chemotherapy via the Median Cubital Vein without implantable central venous access ports port free chemotherapy for metastatic colorectal cancer patients
    International Journal of Clinical Oncology, 2015
    Co-Authors: Yoichiro Yoshida, Seiichiro Hoshino, Naoya Aisu, Masayasu Naito, Syu Tanimura, Ai Mogi, Toshihiro Tanaka, Keiji Hirata, Kazuo Tamura, Yuichi Yamashita
    Abstract:

    Background Repeated venous punctures are usually required during chemotherapy administration for cancer patients. Central venous catheters and implantable port systems have substantially facilitated vascular access, and safe, easy-to-handle port systems have become an integral part of daily clinical routines in oncology. However, several serious complications are associated with central venous ports (CV-ports), and recent developments of combined oral capecitabine and oxaliplatin (XELOX) therapies allow CV-port-free administration. In this study, the safety and efficacy of CV-port-free chemotherapy administration via the Median Cubital Vein was assessed in metastatic colorectal cancer patients.

  • p2 7 6administration of chemotherapy via Median Cubital Vein without central venous access port for colorectal cancer
    Annals of Oncology, 2014
    Co-Authors: Yoichiro Yoshida, Seiichiro Hoshino, Naoya Aisu, Masayasu Naito, Syu Tanimura, Yuichi Yamashita
    Abstract:

    Abstract Background: Repeated venous punctures are usually required in cancer patients for application of chemotherapy. Central venous catheters and implantable port systems have substantially facilitated the problem of vascular access. Safe and easy-to-handle port systems have become an integral part of daily clinical routine in oncology. However, there are several serious complications associated with central venous ports (CV-ports). With the recent development of capecitabine plus oxaliplatin (XELOX) therapy involving oral administration of drug preparations, etc., implantation of a CV-port can be avoided. The present study was undertaken to evaluate the safety of administration of chemotherapy via Median Cubital Vein without CV port for metastatic colorectal cancer. Methods: The study included 144 patients who received XELOX + bevacizumab (BV) therapy and XELOX therapy for metastatic colorectal cancer without implantation of a CV-port. Results: Eighty-five patients experienced vascular pain, but it was transient. The drip infusion route had to be switched to the opposite side because of vascular pain in only 1 of the 144 patients. No patients required CV-port implantation or postponement of treatment due to adverse events caused by administration of the drug via the peripheral Vein. Grade 3 or higher hemotoxicity was noted in 12.5%, and grade 3 or higher nonhematological toxicity was noted in 17.4%. Conclusions: We may be able to perform port-free-chemotherapy via Median Cubital Vein for patients with colorectal cancer. We can avoid the serious complications associated with CV-port.

Erez Nossek - One of the best experts on this subject based on the ideXlab platform.

  • forearm cephalic Vein graft for short middle flow internal maxillary artery to middle cerebral artery bypass
    Neurosurgery, 2015
    Co-Authors: Erez Nossek, Peter Costantino, David J Chalif, Rafael Ortiz, Amir R Dehdashti, David J Langer
    Abstract:

    BACKGROUND: The cervical carotid system has been used as a source of donor vessels for radial artery or saphenous Vein grafts in cerebral bypass. Recently, internal maxillary artery to middle cerebral artery bypass has been described as an alternative, with reduction of graft length potentially correlating with improved patency. OBJECTIVE: To describe our experience using the forearm cephalic Vein grafts for short segment internal maxillary artery to middle cerebral artery bypasses. METHODS: All Vein grafts were harvested from the volar forearm between the proximal Cubital fossa where the Median Cubital Vein is confluent with the cephalic Vein and the distal wrist. RESULTS: Six patients were treated with internal maxillary artery to middle cerebral artery bypass. In 4, the cephalic Vein was used. Postoperative angiography demonstrated good filling of the grafts with robust distal flow. There were no upper extremity vascular complications. All but 1 patient (mortality) tolerated the procedure well. The other 3 patients returned to their neurological baseline with no new neurological deficit during follow-up. CONCLUSION: The internal maxillary artery to middle cerebral artery "middle" flow bypass allows for shorter graft length with both the proximal and distal anastomoses within the same microsurgical field. These unique variable flow grafts represent an ideal opportunity for use of the cephalic Vein of the forearm, which is more easily harvested than the wider saphenous Vein graft and which has good match size to the M1/M2 segments of the middle cerebral artery. The vessel wall is supple, which facilitates handling during anastomosis. There is lower morbidity potential than utilization of the radial artery. Going forward, the cephalic Vein will be our preferred choice for external carotid-internal carotid transplanted conduit bypass.

Kazuo Tamura - One of the best experts on this subject based on the ideXlab platform.

  • administration of chemotherapy via the Median Cubital Vein without implantable central venous access ports port free chemotherapy for metastatic colorectal cancer patients
    International Journal of Clinical Oncology, 2015
    Co-Authors: Yoichiro Yoshida, Seiichiro Hoshino, Naoya Aisu, Masayasu Naito, Syu Tanimura, Ai Mogi, Toshihiro Tanaka, Keiji Hirata, Kazuo Tamura, Yuichi Yamashita
    Abstract:

    Background Repeated venous punctures are usually required during chemotherapy administration for cancer patients. Central venous catheters and implantable port systems have substantially facilitated vascular access, and safe, easy-to-handle port systems have become an integral part of daily clinical routines in oncology. However, several serious complications are associated with central venous ports (CV-ports), and recent developments of combined oral capecitabine and oxaliplatin (XELOX) therapies allow CV-port-free administration. In this study, the safety and efficacy of CV-port-free chemotherapy administration via the Median Cubital Vein was assessed in metastatic colorectal cancer patients.

  • administration of chemotherapy via Median Cubital Vein without implantable central venous access port for metastatic colorectal cancer port free chemotherapy
    Journal of Clinical Oncology, 2014
    Co-Authors: Yoichiro Yoshida, Seiichiro Hoshino, Naoya Aisu, Masayasu Naito, Syu Tanimura, Ai Mogi, Toshihiro Tanaka, Takamitsu Sasaki, Shinsuke Takeno, Kazuo Tamura
    Abstract:

    651 Background: Repeated venous punctures are usually required in cancer patients for application of chemotherapy. Central venous catheters and implantable port systems have substantially facilitated the problem of vascular access. Safe and easy-to-handle port systems have become an integral part of daily clinical routine in oncology. However, there are several serious complications associated with central venous ports (CV-ports). With the recent development of capecitabine plus oxaliplatin (XELOX) therapy involving oral administration of drug preparations, etc., implantation of a CV-port can be avoided. The present study was undertaken to evaluate the safety of administration of chemotherapy via Median Cubital Vein without CV port for metastatic colorectal cancer. Methods: The study included 144 patients who received XELOX + bevacizumab (BV) therapy and XELOX therapy for metastatic colorectal cancer without implantation of a CV-port. Results: Eighty-five patients experienced vascular pain, but it was tra...